Canada Spends Logo

Explore our Budget 2026 analysis

Grant: CIHR - ICR / Cancer Research Society Partnership - Research Grants

McGill University

$65,000.00

An intelligent drug design pipeline incorporating in situ deep mutagenesis to identify allosteric sites of druggable potential in cancer therapeutics

FY 2023-24

Summary
Chemotherapeutic regimes often cause side effects due to drug off-targets and toxicity in normal tissues. In the development of the next generation of highly specific anti-cancer drugs, finding the right protein region to target will be crucial. Here, we propose the integration of a precision genome editing technology in the drug design pipeline to systematically identify druggable regions. We anticipate this approach to be broadly applicable in the development of small-molecule inhibitors against any protein of interest for cancer therapy, including traditionally undruggable targets (e.g. scaffolding proteins).
Program
CIHR - ICR / Cancer Research Society Partnership - Research Grants
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
510987
Name
Cuella Martin Raquel
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Partnername
Cancer Research Society Inc.; Cancer Research Society Inc.
Instname2
Cancer Research
Prcname2
Special Cases
Projecttitle
An intelligent drug design pipeline incorporating in situ deep mutagenesis to identify allosteric sites of druggable potential in cancer therapeutics
Programtype2
Operating Grants
Orgnameinp2
McGill University
Cihramount2
$65,000
Cihrequipment2
$0
Programname2
CIHR - ICR / Cancer Research Society Partnership - Research Grants
Keyworddelim
Early Career Researchers
Abstract
Chemotherapeutic regimes often cause side effects due to drug off-targets and toxicity in normal tissues. In the development of the next generation of highly specific anti-cancer drugs, finding the right protein region to target will be crucial. Here, we propose the integration of a precision genome editing technology in the drug design pipeline to systematically identify druggable regions. We anticipate this approach to be broadly applicable in the development of small-molecule inhibitors against any protein of interest for cancer therapy, including traditionally undruggable targets (e.g. scaffolding proteins).
Competitiondate
202402
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Cuella Martin, Raquel
Approvedterm
2 ans 0 mois
Cihrcontribution2
ICR~ $65,000~ $0~